{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:40:33Z","timestamp":1794638433587,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Innovative Medicines Initiative Joint Undertaking","award":["EMIF grant: 115372"],"award-info":[{"award-number":["EMIF grant: 115372"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13195-018-0428-1","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T16:05:37Z","timestamp":1538064337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8290-8543","authenticated-orcid":false,"given":"Mara","family":"ten Kate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Redolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Peira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvy","family":"Gabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Schaeverbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Blin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill C.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regis","family":"Bordet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Wallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Eckerstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Molinuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"Engelborghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Van Broeckhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Martinez-Lage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalini","family":"Tsolaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans R. J.","family":"Verhey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison L.","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Legido-Quigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bertram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerija","family":"Dobricic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lovestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Streffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bianchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald P.","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Revillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark F.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Wottschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter Jelle","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"428_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer\u2019s disease. Lancet. 2016;388:505\u201317.","journal-title":"Lancet"},{"issue":"Suppl 3","key":"428_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/JAD-2011-0059","volume":"26","author":"EM Reiman","year":"2011","unstructured":"Reiman EM, Langbaum JBS, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, et al. Alzheimer\u2019s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;26(Suppl 3):321\u20139.","journal-title":"J Alzheimers Dis"},{"key":"428_CR3","doi-asserted-by":"publisher","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","volume":"6","author":"RA Sperling","year":"2014","unstructured":"Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6:228fs13.","journal-title":"Sci Transl Med"},{"key":"428_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S2215-0366(15)00454-X","volume":"3","author":"CW Ritchie","year":"2016","unstructured":"Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van der Geyten S, Lovestone S, et al. Development of interventions for the secondary prevention of Alzheimer\u2019s dementia: the European Prevention of Alzheimer\u2019s Dementia (EPAD) project. Lancet Psychiatry. 2016;3:179\u201386.","journal-title":"Lancet Psychiatry"},{"key":"428_CR5","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1924\u201338.","journal-title":"JAMA"},{"key":"428_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13195-017-0299-x","volume":"9","author":"M Ten Kate","year":"2017","unstructured":"Ten Kate M, Barkhof F, Visser PJ, Teunissen CE, Scheltens P, van der Flier WM, et al. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimers Res Ther. 2017;9:73.","journal-title":"Alzheimers Res Ther"},{"key":"428_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/brain\/awv007","volume":"138","author":"W Huijbers","year":"2015","unstructured":"Huijbers W, Mormino EC, Schultz AP, Wigman S, Ward AM, Larvie M, et al. Amyloid-\u03b2 deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain. 2015;138:1023\u201335.","journal-title":"Brain"},{"key":"428_CR8","doi-asserted-by":"publisher","first-page":"12686","DOI":"10.1523\/JNEUROSCI.3189-09.2009","volume":"29","author":"T Hedden","year":"2009","unstructured":"Hedden T, Dijk KRAV, Becker JA, Mehta A, Sperling RA, Johnson KA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009;29:12686\u201394.","journal-title":"J Neurosci"},{"key":"428_CR9","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1001\/archneurol.2009.272","volume":"66","author":"M Storandt","year":"2009","unstructured":"Storandt M, Mintun M, Head D, Morris J. Cognitive decline and brain volume loss as signatures of cerebral amyloid-\u03b2 peptide deposition identified with Pittsburgh compound b: cognitive decline associated with A\u03b2 deposition. Arch Neurol. 2009;66:1476\u201381.","journal-title":"Arch Neurol"},{"key":"428_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/cercor\/bhn113","volume":"19","author":"BC Dickerson","year":"2009","unstructured":"Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, et al. The cortical signature of Alzheimer\u2019s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497\u2013510.","journal-title":"Cereb Cortex"},{"key":"428_CR11","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/ana.22333","volume":"69","author":"JA Becker","year":"2011","unstructured":"Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, et al. Amyloid-\u03b2 associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69:1032\u201342.","journal-title":"Ann Neurol"},{"key":"428_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.neuroimage.2013.02.030","volume":"74","author":"D Tosun","year":"2013","unstructured":"Tosun D, Joshi S, Weiner MW. Alzheimer\u2019s Disease Neuroimaging Initiative. Neuroimaging predictors of brain amyloidosis in mild cognitive impairment. Ann Neurol. 2013;74:188\u201398.","journal-title":"Ann Neurol"},{"key":"428_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13195-018-0396-5","volume":"10","author":"I Bos","year":"2018","unstructured":"Bos I, Vos S, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni G, et al. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimers Res Ther. 2018;10:64.","journal-title":"Alzheimers Res Ther"},{"key":"428_CR14","first-page":"254","volume":"30","author":"PJ Visser","year":"2008","unstructured":"Visser PJ, Verhey FRJ, Boada M, Bullock R, Deyn PPD, Frisoni GB, et al. Development of screening guidelines and clinical criteria for predementia Alzheimer\u2019s disease. NED. 2008;30:254\u201365.","journal-title":"NED"},{"key":"428_CR15","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3233\/JAD-160766","volume":"60","author":"BLR Reijs","year":"2017","unstructured":"Reijs BLR, Ramakers IHGB, K\u00f6hler S, Teunissen CE, Koel-Simmelink M, Nathan PJ, et al. Memory correlates of Alzheimer\u2019s disease cerebrospinal fluid markers: a longitudinal cohort study. J Alzheimers Dis. 2017;60:1119\u201328.","journal-title":"J Alzheimers Dis"},{"key":"428_CR16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/joim.12482","volume":"279","author":"S Galluzzi","year":"2016","unstructured":"Galluzzi S, Marizzoni M, Babiloni C, Albani D, Antelmi L, Bagnoli C, et al. Clinical and biomarker profiling of prodromal Alzheimer\u2019s disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a \u2018European ADNI study\u2019. J Intern Med. 2016;279:576\u201391.","journal-title":"J Intern Med"},{"key":"428_CR17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/JAD-132306","volume":"41","author":"WM van der Flier","year":"2014","unstructured":"van der Flier WM, Pijnenburg YAL, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41:313\u201327.","journal-title":"J Alzheimers Dis"},{"key":"428_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.neurobiolaging.2015.10.018","volume":"38","author":"M Ten Kate","year":"2016","unstructured":"Ten Kate M, Sanz-Arigita EJ, Tijms BM, Wink AM, Clerigue M, Garcia-Sebastian M, et al. Impact of APOE-\u025b4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. Neurobiol Aging. 2016;38:14\u201320.","journal-title":"Neurobiol Aging"},{"key":"428_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3233\/JAD-151097","volume":"54","author":"C Somers","year":"2016","unstructured":"Somers C, Struyfs H, Goossens J, Niemantsverdriet E, Luyckx J, De Roeck N, et al. A decade of cerebrospinal fluid biomarkers for Alzheimer\u2019s disease in Belgium. J Alzheimers Dis. 2016;54:383\u201395.","journal-title":"J Alzheimers Dis"},{"key":"428_CR20","first-page":"3879","volume":"27","author":"K Adamczuk","year":"2017","unstructured":"Adamczuk K, De Weer A-S, Nelissen N, Dupont P, Sunaert S, Bettens K, et al. Functional changes in the language network in response to increased amyloid \u03b2 deposition in cognitively intact older adults. Cereb Cortex. 2017;27:3879.","journal-title":"Cereb Cortex"},{"key":"428_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3233\/JAD-170335","volume":"60","author":"A Oikonomidi","year":"2017","unstructured":"Oikonomidi A, Tautvydait\u0117 D, Gholamrezaee MM, Henry H, Bacher M, Popp J. Macrophage migration inhibitory factor is associated with biomarkers of Alzheimer\u2019s disease pathology and predicts cognitive decline in mild cognitive impairment and mild dementia. J Alzheimers Dis. 2017;60:273\u201381.","journal-title":"J Alzheimers Dis"},{"key":"428_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/jcbfm.2015.147","volume":"36","author":"A Wallin","year":"2016","unstructured":"Wallin A, Nordlund A, Jonsson M, Lind K, Edman \u00c5, G\u00f6thlin M, et al. The Gothenburg MCI study: design and distribution of Alzheimer\u2019s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. J Cereb Blood Flow Metab. 2016;36:114\u201331.","journal-title":"J Cereb Blood Flow Metab"},{"key":"428_CR23","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3233\/JAD-2010-100678","volume":"22","author":"J Fortea","year":"2010","unstructured":"Fortea J, Sala-Llonch R, Bartr\u00e9s-Faz D, Bosch B, Llad\u00f3 A, Bargall\u00f3 N, et al. Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. J Alzheimers Dis. 2010;22:909\u201322.","journal-title":"J Alzheimers Dis"},{"key":"428_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00259-015-3156-9","volume":"43","author":"K Adamczuk","year":"2016","unstructured":"Adamczuk K, Schaeverbeke J, Nelissen N, Neyens V, Vandenbulcke M, Goffin K, et al. Amyloid imaging in cognitively normal older adults: comparison between (18)F-flutemetamol and (11)C-Pittsburgh compound B. Eur J Nucl Med Mol Imaging. 2016;43:142\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"428_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319\u201329.","journal-title":"Ann Neurol"},{"key":"428_CR26","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","volume":"55","author":"P Scheltens","year":"1992","unstructured":"Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in \u201cprobable\u201d Alzheimer\u2019s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967\u201372.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"428_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000117270","volume":"36","author":"F Pasquier","year":"1996","unstructured":"Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol. 1996;36:268\u201372.","journal-title":"Eur Neurol"},{"key":"428_CR28","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1007\/s00330-011-2205-4","volume":"21","author":"ELGE Koedam","year":"2011","unstructured":"Koedam ELGE, Lehmann M, van der Flier WM, Scheltens P, YAL P, Fox N, et al. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol. 2011;21:2618\u201325.","journal-title":"Eur Radiol"},{"key":"428_CR29","first-page":"421","volume":"8","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. Am J Neuroradiol. 1987;8:421\u20136.","journal-title":"Am J Neuroradiol"},{"key":"428_CR30","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuroimage.2012.01.021","volume":"62","author":"B Fischl","year":"2012","unstructured":"Fischl B. FreeSurfer. Neuroimage. 2012;62:774\u201381.","journal-title":"Neuroimage"},{"key":"428_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack","year":"2017","unstructured":"Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 2017;13:205\u201316.","journal-title":"Alzheimers Dement"},{"key":"428_CR32","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.neubiorev.2012.01.004","volume":"36","author":"G Orr\u00f9","year":"2012","unstructured":"Orr\u00f9 G, Petterson-Yeo W, Marquand AF, Sartori G, Mechelli A. Using support vector machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review. Neurosci Biobehav Rev. 2012;36:1140\u201352.","journal-title":"Neurosci Biobehav Rev"},{"key":"428_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1145\/1961189.1961199","volume":"2","author":"C-C Chang","year":"2011","unstructured":"Chang C-C, Lin C-J. LIBSVM: A Library for Support Vector Machines. ACM Trans Intell Syst Technol. 2011;2:27 1\u201327:27.","journal-title":"ACM Trans Intell Syst Technol"},{"key":"428_CR34","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: Machine Learning in Python. J Mach Learn Res. 2011;12:2825\u201330.","journal-title":"J Mach Learn Res"},{"key":"428_CR35","doi-asserted-by":"publisher","first-page":"6562","DOI":"10.1073\/pnas.102102699","volume":"99","author":"C Ambroise","year":"2002","unstructured":"Ambroise C, McLachlan GJ. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci U S A. 2002;99:6562\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"428_CR36","first-page":"2079","volume":"11","author":"GC Cawley","year":"2010","unstructured":"Cawley GC, Talbot NLC. On over-fitting in model selection and subsequent selection bias in performance evaluation. J Mach Learn Res. 2010;11:2079\u2013107.","journal-title":"J Mach Learn Res"},{"key":"428_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/978-1-4419-9326-7_5","volume-title":"Ensemble Machine Learning: Methods and Applications [Internet]","author":"A Cutler","year":"2012","unstructured":"Cutler A, Cutler DR, Stevens JR. Random Forests. In: Zhang C, Ma Y, editors. Ensemble Machine Learning: Methods and Applications [Internet]. Boston: Springer US; 2012. p. 157\u201375. Available from: \n                    https:\/\/doi.org\/10.1007\/978-1-4419-9326-7_5\n                    \n                  ."},{"key":"428_CR38","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1001\/jamaneurol.2014.446","volume":"71","author":"N Mattsson","year":"2014","unstructured":"Mattsson N, Insel PS, Nosheny R, Tosun D, Trojanowski JQ, Shaw LM, et al. Emerging \u03b2-amyloid pathology and accelerated cortical atrophy. JAMA Neurol. 2014;71:725\u201334.","journal-title":"JAMA Neurol"},{"key":"428_CR39","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2013.01.016","volume":"34","author":"M Pievani","year":"2013","unstructured":"Pievani M, Bocchetta M, Boccardi M, Cavedo E, Bonetti M, Thompson PM, et al. Striatal morphology in early-onset and late-onset Alzheimer\u2019s disease: a preliminary study. Neurobiol Aging. 2013;34:1728\u201339.","journal-title":"Neurobiol Aging"},{"key":"428_CR40","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1212\/WNL.0000000000001231","volume":"84","author":"LG Apostolova","year":"2015","unstructured":"Apostolova LG, Hwang KS, Avila D, Elashoff D, Kohannim O, Teng E, et al. Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures. Neurology. 2015;84:729\u201337.","journal-title":"Neurology"},{"key":"428_CR41","first-page":"357","volume-title":"Prediction of Amyloidosis from Neuropsychological and MRI Data for Cost Effective Inclusion of Pre-symptomatic Subjects in Clinical Trials. Deep Learning in Medical Image Analysis and Multimodal Learning for Clinical Decision Support [Internet]","author":"M Ansart","year":"2017","unstructured":"Ansart M, Epelbaum S, Gagliardi G, Colliot O, Dormont D, Dubois B, et al. Prediction of Amyloidosis from Neuropsychological and MRI Data for Cost Effective Inclusion of Pre-symptomatic Subjects in Clinical Trials. Deep Learning in Medical Image Analysis and Multimodal Learning for Clinical Decision Support [Internet]. Cham: Springer; 2017. p. 357\u201364. [cited 2018 Jan 11] Available from: \n                    https:\/\/link.springer.com\/chapter\/10.1007\/978-3-319-67558-9_41"},{"key":"428_CR42","first-page":"76","volume":"4","author":"PS Insel","year":"2016","unstructured":"Insel PS, Palmqvist S, Mackin RS, Nosheny RL, Hansson O, Weiner MW, et al. Assessing risk for preclinical \u03b2-amyloid pathology with APOE, cognitive, and demographic information. Alzheimers Dement. 2016;4:76\u201384.","journal-title":"Alzheimers Dement"},{"key":"428_CR43","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1212\/WNL.0b013e31826e2696","volume":"79","author":"MM Mielke","year":"2012","unstructured":"Mielke MM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Roberts RO, et al. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology. 2012;79:1570\u20137.","journal-title":"Neurology"},{"key":"428_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1023\/A:1009715923555","volume":"2","author":"CJC Burges","year":"1998","unstructured":"Burges CJC. A tutorial on support vector machines for pattern recognition. Data Min Knowl Disc. 1998;2:121\u201367.","journal-title":"Data Min Knowl Disc"},{"key":"428_CR45","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/B978-044452855-1\/50015-5","volume-title":"Outcome Prediction in Cancer [Internet]","author":"M Kounelakis","year":"2007","unstructured":"Kounelakis M, Zervakis M, Kotsiakis X. Chapter 13\u2014the impact of microarray technology in brain cancer. In: AFG T, Fisher AC, editors. Outcome Prediction in Cancer [Internet]. Amsterdam: Elsevier; 2007. p. 339\u201388. [cited 2018 Aug 1] Available from: \n                    http:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780444528551500155\n                    \n                  ."},{"key":"428_CR46","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","volume":"74","author":"S Janelidze","year":"2017","unstructured":"Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, et al. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol. 2017;74:1492\u2013501.","journal-title":"JAMA Neurol"},{"key":"428_CR47","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-160722","volume":"55","author":"P Lewczuk","year":"2017","unstructured":"Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, et al. Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer\u2019s disease. J Alzheimers Dis. 2017;55:813\u201322.","journal-title":"J Alzheimers Dis"},{"key":"428_CR48","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awu367","volume":"138","author":"N Mattsson","year":"2015","unstructured":"Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-\u03b2 and florbetapir imaging in Alzheimer\u2019s disease. Brain. 2015;138:772\u201383.","journal-title":"Brain"},{"key":"428_CR49","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/brain\/aww015","volume":"139","author":"S Palmqvist","year":"2016","unstructured":"Palmqvist S, Mattsson N, Hansson O. Alzheimer\u2019s Disease Neuroimaging Initiative. Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography. Brain. 2016;139:1226\u201336.","journal-title":"Brain"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0428-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-018-0428-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0428-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T19:08:12Z","timestamp":1569524892000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-018-0428-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1186\/s13195-018-0428-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]},"assertion":[{"value":"10 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The local medical ethics committee in each centre approved the study. Subjects had already provided written informed consent at the time of inclusion in the cohort for use of data, samples and scans.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. HZ has served on scientific advisory boards of Eli Lilly and Roche Diagnostics, has received travel support from Teva and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. MFG\u2019s current employer is Teva Pharmaceuticals, Inc., Malvern, PA, USA; his former employer was Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. Any views expressed in this publication represent the personal opinions of the authors and not those of their respective employer. JCR is a full-time employee of GlaxoSmithkline. PM-L reports personal fees from Lilly, Axon, General Electric and Nutricia for advisory boards, and lecturing fees from Lilly, Nutricia, Piramal. RV was principal investigator of the phase 1 and 2 [<sup>18<\/sup>F]flutemetamol trials. RV\u2019s institution has clinical trial agreements (RV as PI) with AbbVie, Biogen, EliLilly, Merck and Novartis, and consultancy agreements (RV as PI) with Novartis and Cytox Ltd. SL has done consultancy for Eaisi, EIP Pharma, SomaLogic, Merck and Optum Labs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"100"}}